Medtronic is set to launch its Neurovascular Co-Lab Platform for accelerating innovation in stroke care and treatment.
The new platform has been designed for transforming ideas and technologies into new therapies by providing insight, support and scalability to physicians, innovators and start-ups.
It will drive collaboration and connections to help bring neurovascular innovations to life.
Planned to be launched on 29 October, the Neurovascular Co-Lab Platform aims to improve stroke treatment and access for patients around the world.
It is an always-on virtual portal for neurovascular innovator submissions, which will be evaluated and prioritised to determine potential paths forward.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataSee Also:
The selected opportunities will be progressed based on their individual requirements, such as revealing innovators to Medtronic‘s experts’ network, leaders and partners for collaboration, clinical study funding, and strategic and directional guidance.
Medtronic Neuroscience Portfolio president and executive vice-president Brett Wall said: “Medtronic has always invested in innovative stroke treatment technologies leading the standard of care and advancing the practice of neurosurgery.
“The neurovascular market has enormous growth potential, and we invite innovative start-ups, physicians, venture-capital firms and inventors to collaborate with us as we set out to change stroke care as we know it today.”
Prior to this development, the company announced plans to separate its combined Patient Monitoring and Respiratory Interventions businesses (NewCo), which are part of the Medtronic Medical Surgical Portfolio.
This decision was taken to create value for all Medtronic stakeholders, allow the company to focus more on strategic priority areas and execute its leadership strategy in the medtech markets that leverage its strengths.
